Thursday, May 9, 1:52 PM
NPS Pharmaceuticals (NPSP +5.2%) moves up today after its Q1 bottom line comes in better than Street estimates. Net losses on a per share basis were 25% lower than the prior year on higher royalty revenue and the company begins to see its rollout of Gattex take hold. It comfirms financial guidance for 2013, and says it continues to expect its operating expenses to be between $135M and $145M.
Wednesday, April 24, 9:24 AM
Oppenheimer initiates NPS Pharmaceuticals (NPSP) at Outperform with a price target of $18. "There are no direct competitors for Gattex and Natpara," writes analyst Boris Peaker, adding that investors shouldn't be wary of "owning a launch name" in this case because the company's "first-in-class compounds [should] generate substantial commercial traction given their therapeutic benefits." Shares +1.81% premarket.
Comment![On the Move, Healthcare]
Tuesday, March 19, 8:18 AM
NPS Pharmaceuticals (NPSP) has bought back the none-North American rights to two drugs from Takeda for $50M in shares and possible milestone payments, giving NPS with full global rights to the treatments. The drugs are Revestive (Gattex in the U.S.), a medicine for short bowel syndrome, and Preotact, a thyroid hormone replacement therapy. (PR)
Friday, December 21, 2012, 4:04 PM
NPS Pharmaceuticals (NPSP +04%) says the FDA has approved Gattex for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support. The company says Gattex will be available in Q113.
Friday, November 9, 2012, 8:07 AMNPS Pharmaceuticals (NPSP): Q3 EPS of -$0.04 beats by $0.12. Revenue of $27M (+9.8% Y/Y) misses by $1.2M. (PR)